Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|October 27, 2014
FUJIFILM Announces Agreement to Acquire Kalon Biotherapeutics
Author(s)Ashley Roberts
FUJIFILM announced an agreement to acquire Kalon Biotherapeutics, a biopharmaceutical contract manufacturing organization specializing in vaccine manufacturing.
Advertisement
FUJIFILM Corp. will enter the vaccine CMO market with the acquisition of Kalon Biotherapeutics, a biologics development and manufacturing service provider out of Texas. FUJIFILM subsidiary, FUJIFILM Diosynth Biotechnologies (FDBU), will acquire 49% of the total membership interests in Kalon and will be entitled to appoint a majority of Kalon’s board members. Based on milestone achievements, FDBU may acquire 100% interest share.
The acquisition will strengthen FUJIFILM’s stance in the pharmaceutical industry. This announcement comes shortly after the announcement that FUJIFILM would start producing
Source:
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5